In a patient with HER2‑positive early‑stage breast cancer who has residual invasive disease after neoadjuvant chemotherapy with trastuzumab (± pertuzumab) and surgery, what is the recommended adjuvant trastuzumab deruxtecan regimen, including dose, duration, cardiac and interstitial lung disease monitoring, and alternative options if contraindicated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board

Educational purpose only • Exercise caution as content is pending human review

Article Review Status

Submitted

Under Review

Approved

Last updated: March 3, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Related Questions

What adjuvant systemic anti-HER2 (Trastuzumab) therapy is recommended for a patient with HER2-positive breast cancer who received neoadjuvant chemotherapy with Epirubicin, Cyclophosphamide, Docetaxel, and Herceptin (Trastuzumab) for 6 cycles, followed by mastectomy and axillary clearance, and was found to have residual invasive carcinoma grade 3?

For a 66-year-old postmenopausal woman with residual invasive disease after neoadjuvant therapy for triple-positive breast cancer, who has only received Trastuzumab (trastuzumab), what is the recommended adjuvant therapy, T-DM1 (ado-trastuzumab emtansine) or Pertuzumab (pertuzumab)?

What is the recommended pertuzumab dosing regimen for HER2‑positive breast cancer?

What are the alternative treatment options for a post-operative patient with residual invasive disease after neoadjuvant chemotherapy and Herceptin (trastuzumab) for HER2-positive breast cancer, who is unable to receive T-DM1 (ado-trastuzumab emtansine)?

What are the guidelines for chemotherapy in breast carcinoma?

What is the recommended treatment plan for Myasthenia gravis?

Can you simplify and provide examples for each manic symptom of bipolar disorder?

In a 74-year-old woman with heart failure and a serum potassium of 2.6 mEq/L, should I administer potassium chloride 50 mEq diluted in 500 mL of normal saline via a peripheral IV line over 20 hours?

Does escitalopram affect the pharmacodynamics of general anesthetic agents or peri‑operative management?

What is the significance and recommended management of a low thyroid-stimulating hormone (TSH) with normal free thyroxine (free T4) and free triiodothyronine (free T3)?

What are the symptoms of leprosy (Hansen disease)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.